Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 432 across all filing types
Latest filing 2018-04-12 Report Publication Anno…
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
Invitation to presentation of BioArctic’s Interim Report January – March 2018 on April 26, 2018
Report Publication Announcement Classification · 1% confidence The document is a press release explicitly titled "Invitation to presentation of BioArctic's Interim Report January – March 2018 on April 26, 2018." It announces the future publication date (April 26, 2018) of the Interim Report and invites stakeholders to an audiocast/teleconference to discuss that report. Since the document itself is an announcement about the release of a report (the Interim Report) and an associated presentation/call, and given its short length (2148 chars), it fits the definition of a Report Publication Announcement (RPA). It is not the Interim Report (IR) itself, nor is it the Call Transcript (CT), as it is the invitation to the call, not the transcript of the call.
2018-04-12 English
BioArctic får myndighetsgodkännande i Norge för klinisk studie med patienter som har komplett ryggmärgsskada
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces that BioArctic has received regulatory approval in Norway (NOMA) to include Norwegian patients in their ongoing clinical Phase 1/2 study (SC0806) for complete spinal cord injury. It details the study, mentions regulatory compliance (EU Market Abuse Regulation), and provides contact information. This format—a brief, timely announcement of a specific corporate or regulatory event (clinical trial progress/approval)—is characteristic of a general regulatory announcement or press release that doesn't fit the specific definitions of 10-K, ER, or IR. Since it is a formal announcement required for public disclosure, and it doesn't fit the more specific categories like Director's Dealing (DIRS), Dividend (DIV), or Earnings Release (ER), the most appropriate general category for such regulatory news is Regulatory Filings (RNS). The document length (4533 chars) is not extremely short, but the content is purely an announcement of an event, not the detailed report itself.
2018-03-21 Swedish
BioArctic receives regulatory approval in Norway for a clinical study in patients with Complete Spinal Cord Injury
Regulatory Filings Classification · 1% confidence The document is a press release announcing that BioArctic AB received regulatory approval from the Norwegian Medicines Agency (NOMA) to include Norwegian patients in an ongoing clinical Phase 1/2 study for their product SC0806. This is a specific operational update regarding clinical trials and regulatory milestones, not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a formal shareholder communication (like DEF 14A or AGM-R). Since it is a specific announcement about regulatory progress and clinical development, it does not fit neatly into the primary financial categories. It is best classified as a general Regulatory Filing (RNS) as it is a public disclosure mandated by regulations (EU Market Abuse Regulation mentioned at the end) concerning company operations, or potentially a Legal Proceedings Report (LTR) if the focus was on litigation, but here it is a positive regulatory step. Given the options, RNS serves as the best general category for non-financial, operational regulatory news releases that don't fit elsewhere.
2018-03-21 English
BioArctic får patentskydd i Japan för en medicinteknisk produkt för behandling av patienter med komplett ryggmärgsskada
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces that the Japanese patent office will grant a patent for a medical device/drug combination (SC0806) for treating complete spinal cord injury. It includes a date (March 19, 2018), contact information, and a concluding statement about being information that BioArctic AB is required to disclose under the EU Market Abuse Regulation. This structure is characteristic of a general corporate announcement or regulatory disclosure that is not a formal financial report (like 10-K, IR, or ER). Since it is a specific announcement regarding intellectual property/product development status, it does not fit well into the primary financial reporting categories. It is a specific corporate update, but given the options, it is best classified as a general Regulatory Filing (RNS) as it is a mandatory disclosure under MAR, or potentially a Legal Proceedings Report (LTR) if patents were considered legal matters, but RNS is the broader fallback for mandatory, non-financial disclosures. Given the nature of the announcement (patent grant), it is a significant corporate event disclosure, making RNS the most appropriate general regulatory category when specific categories like 'IP' (which is not an option) are unavailable, or it could be seen as a general announcement. Since it is a formal disclosure required by regulation (MAR), RNS is the best fit among the provided codes for a non-financial, mandatory announcement.
2018-03-19 Swedish
BioArctic receives patent protection in Japan for a medical device for treatment of patients with Complete Spinal Cord Injury
Regulatory Filings Classification · 1% confidence The document is a press release announcing that the Japanese Patent Office granted a patent for a medical device related to the product candidate SC0806 for treating Complete Spinal Cord Injury. This announcement concerns intellectual property protection and is not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). It is a specific corporate update regarding legal/patent status. Since there is no specific category for 'Patent Grant Announcement,' and it is a formal announcement of a legal/regulatory development concerning the company's assets, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory announcements not covered by more specific codes like DIRS or LTR (which usually implies litigation/regulatory action, not IP grant). Given the nature of the announcement (patent grant notification), RNS is the most appropriate general regulatory category.
2018-03-19 English
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 1% confidence The document explicitly details a change in shareholding by 'Old Mutual Global Investors (UK) Ltd' in 'BioArctic AB'. Key phrases include 'Reason for major shareholding notification Buy', 'Before the transaction', 'After the transaction', and the resulting 'Percentage' of ownership crossing a threshold (implied by the notification structure). This content directly corresponds to the definition of a Major Shareholding Notification, which is classified as 'MRQ'. The document is a formal report of the transaction, not an announcement of a report.
2018-03-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.